Cargando…
Daratumumab-(225)Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cellular phagocyto...
Autores principales: | Dawicki, Wojciech, Allen, Kevin J.H., Jiao, Rubin, Malo, Mackenzie E., Helal, Muath, Berger, Mark S., Ludwig, Dale L., Dadachova, Ekaterina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682347/ https://www.ncbi.nlm.nih.gov/pubmed/31413916 http://dx.doi.org/10.1080/2162402X.2019.1607673 |
Ejemplares similares
-
Synthesis and Stability of Actinium-225 Endohedral
Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020) -
Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020) -
An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018) -
The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum
por: Kleynhans, Janke, et al.
Publicado: (2022) -
225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
por: Garg, Ravendra, et al.
Publicado: (2020)